The company through its partner aims to capture a significant share of the Japanese Glargine market
Biocon has announced that after receiving approval for its insulin Glargine from the Japanese regulator last quarter, its partner FUJIFILM Pharma (FFP) has launched the product in Japan.
Insulin Glargine BS Injection Kit has been developed and manufactured by Biocon, and is being commercialised by FFP in Japan. The product is a ready-to-use, prefilled disposable pen with 3 ml of 100IU insulin Glargine. It will provide a high quality, yet affordable, world-class long-acting biosimilar basal insulin Glargine for patients of diabetes in Japan.
The company through its partner aims to capture a significant share of the Japanese Glargine market of $ 144 million, which is reportedly the second largest market outside of North America and Europe and is largely dominated by disposable pens.
Kiran Mazumdar-Shaw, Biocon, Chairperson & Managing Director said, “The launch of our biosimilar Insulin Glargine in Japan by our partner, furthers our mission to provide affordable access to high quality biopharmaceuticals for chronic diseases. We believe with FUJIFILM Pharma’s commercial network, we will enable access to this world-class, prefilled disposable pen for better diabetes management for patients in Japan.”
The company currently has marketing approvals in over 60 countries for rh-Insulin and in over 20 countries for insulin Glargine. It is also developing insulin Glargine for the developed markets outside of Japan in collaboration with Mylan.